Angioedema clinical trial pipeline analysis highlights key companies developing innovative treatments
From GlobeNewswire: 2025-05-06 13:00:00
Angioedema Clinical Trial Pipeline Analysis reveals 15+ key companies set to transform treatment. Rising allergic conditions and HAE diagnosis drive market growth. DelveInsight’s report covers global pipeline therapies, with major companies like Ionis Pharmaceuticals, Inc., Astria Therapeutics, and more developing innovative treatments. Promising therapies like Donidalorsen, STAR-0215, and NTLA-2002 are in various clinical trial phases.
In March 2025, a study highlighted the importance of controlling HAE symptoms for a better quality of life. Astria Therapeutics initiated a Phase III trial for navenibart in HAE patients in February 2025. Pharvaris received orphan designation in Europe for deucrictibant in January 2025. Intellia Therapeutics and KalVista also made significant advancements in their HAE treatment trials.
The angioedema pipeline report offers comprehensive insights into emerging therapies and key players in the field. It includes detailed profiles of pipeline assets, analysis of clinical and non-clinical stage drugs, and an assessment of opportunities and risks. Discover the latest advancements in angioedema treatments and clinical trials for a deeper understanding of the landscape.
Angioedema is characterized by sudden, localized swelling in deeper skin layers and mucous membranes, potentially life-threatening when affecting the airway. It can be triggered by histamine, bradykinin, or other mediators. Symptoms include swelling, rashes, abdominal pain, and breathing difficulties. Diagnosis involves clinical assessment, history review, and diagnostic tests.
Treatment varies based on angioedema type and severity. Allergic cases may require antihistamines or epinephrine, while hereditary angioedema focuses on prevention and management with targeted therapies. In emergencies, immediate medical care is crucial to prevent airway obstruction. Understanding the underlying cause is essential for effective treatment.
Explore the latest angioedema drugs and clinical trials to stay informed about emerging therapies and advancements in the field. DelveInsight’s detailed reports on angioedema pipeline and therapeutics provide valuable insights into the landscape, helping stakeholders make informed decisions and drive innovation in treatment options. Discover the future of angioedema treatment with comprehensive insights from industry experts.
Read more at GlobeNewswire: Angioedema Clinical Trial Pipeline Analysis Demonstrates